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Abstract 
 Low-grade sustained inflammation links obesity to insulin resistance and 
nonalcoholic fatty liver disease (NAFLD). However, therapeutic approaches to 
improve systemic energy balance and chronic inflammation in obesity are limited. 
Pharmacological activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
alleviates obesity and insulin resistance in mice; however, Nrf2 inducers are not 
clinically available owing to safety concerns. Thus, we examined whether dietary 
glucoraphanin, a stable precursor of the Nrf2 inducer sulforaphane, ameliorates 
systemic energy balance, chronic inflammation, insulin resistance, and NAFLD in 
high-fat diet (HFD)-fed mice. Glucoraphanin supplementation attenuated weight gain, 
decreased hepatic steatosis, and improved glucose tolerance and insulin sensitivity in 
HFD-fed wild-type mice but not in HFD-fed Nrf2-knockout mice. Compared with 
vehicle-treated controls, glucoraphanin-treated HFD-fed mice had lower plasma 
lipopolysaccharide levels and decreased relative abundance of the Gram-negative 
bacterial family Desulfovibrionaceae in their gut microbiomes. In HFD-fed mice, 
glucoraphanin increased energy expenditure and the protein expression of uncoupling 
protein 1 (Ucp1) in inguinal and epididymal adipose depots. Additionally, in this 
group, glucoraphanin attenuated hepatic lipogenic gene expression, lipid 
peroxidation, classically activated M1-like macrophage accumulation, and 
inflammatory signaling pathways. By promoting fat browning, limiting metabolic 
endotoxemia-related chronic inflammation, and modulating redox stress, 
glucoraphanin may mitigate obesity, insulin resistance, and NAFLD. 
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Low-grade sustained inflammation, triggered by chronically high levels of 
proinflammatory cytokines and gut microbiota-derived circulatory lipopolysaccharide 
(LPS), links obesity with comorbidities such as insulin resistance and nonalcoholic fatty 
liver disease (NAFLD) (1,2). Although a number of pharmacological treatments for obesity 
and NAFLD have been tested, few drugs are clinically available owing to the lack of long-
term efficacy and safety concerns (3,4). Thus, a novel therapeutic approach that would 
improve energy metabolism and reduce chronic inflammation in obesity is sorely needed.  
 Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a basic leucine zipper 
transcription factor, is widely expressed in human and mouse tissues, and serves as a 
defense response against extrinsic and intrinsic stressors (5). Upon exposure to electrophilic 
and oxidative stress, Nrf2 detaches from its repressor, Kelch-like ECH-associated protein 
1-nuclear factor (Keap1), and is translocated from the cytoplasm into the nucleus. This 
translocation leads to the transcriptional activation of genes encoding phase 2 detoxifying 
and antioxidant enzymes (6). In addition to the ubiquitous induction of cytoprotective 
genes, Nrf2 regulates a large number of genes involved in glucose and lipid metabolism. In 
the liver, the constitutive activation of Nrf2 via Keap1 knockdown represses the expression 
of genes involved in gluconeogenesis (7) and lipogenesis (8), thereby alleviating obesity, 
diabetes, and hepatic steatosis. Accordingly, synthetic Nrf2 inducers such as synthetic 
triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO)-imidazolide (9), 
CDDO-methyl ester (known as bardoxolone methyl) (10), and dithiolethione analog, 
oltipraz (11), have been shown to ameliorate high-fat diet (HFD)-induced obesity and 
diabetes. These synthetic Nrf2 inducers also decrease liver and adipose tissue lipogenesis, 
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and enhance glucose uptake in skeletal muscles. However, the mechanisms by which Nrf2 
enhances energy metabolism in response to a HFD remain largely unknown. Although 
enhanced Nrf2 signaling has shown promising results in several animal studies, the 
synthetic Nrf2 inducers have caused adverse cardiac events and gastrointestinal toxicities in 
clinical trials (12,13). These observations prompted us to explore a safer Nrf2 inducer for 
the treatment of obesity, insulin resistance, and NAFLD. 
 Sulforaphane, an isothiocyanate derived from cruciferous vegetables, is one of the 
most potent naturally occurring Nrf2 inducers; this compound exhibits anticancer activity 
in cancer cell lines and in carcinogen-induced rodent models (14). Among the cruciferous 
vegetables, broccoli sprouts are the best source of glucoraphanin, a stable glucosinolate 
precursor of sulforaphane (15). In both rodents and humans, glucoraphanin is hydrolyzed 
by gut microbiota-derived myrosinase into bioactive sulforaphane prior to intestinal 
absorption (16). A recent clinical study demonstrated the safety of orally administered 
glucoraphanin (17). In the present study, we examined the dietary glucoraphanin-mediated 
modulation of systemic energy balance and the mitigation of chronic inflammation, insulin 
resistance, and NAFLD in diet-induced obese mice. 
 
Research Design and Methods 
Glucoraphanin preparation 
 The sulforaphane precursor, glucoraphanin, was prepared as previously described 
(17) with minor modifications. Briefly, one day after germination from broccoli seeds 
(Caudill Seed Company, Louisville, KY), sprouts were boiled in water for 30 min. The 
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water extract was mixed with dextrinized cornstarch and subsequently spray-dried to yield 
an extract powder containing 135 mg of glucoraphanin per gram (0.31 mmol/g) (18). The 
total glucoraphanin titer in the resulting powder was determined by HPLC as previously 
reported (19). 
 
Mice and diets 
 Male C57BL/6JSlc mice were purchased from Japan SLC (Hamamatsu, Japan) at 7 
weeks of age. Nrf2-knockout (Nrf2
-/-
) mouse strain (RBRC01390; C57BL/6J background) 
was provided by RIKEN BRC (Tsukuba, Japan) (6). After a week of acclimation, mice 
were fed normal chow (NC; containing 2.2% dextrinized cornstarch, 10% kcal from fat, 
#D12450B; Research Diets, New Brunswick, NJ), NC containing 0.3% glucoraphanin (NC-
GR; containing 2.2% extract powder), a high-fat diet (HFD; containing 2.2% dextrinized 
cornstarch, 60% kcal from fat, #D12492; Research diets), or a HFD containing 0.3% 
glucoraphanin (HFD-GR; containing 2.2% extract powder) for 14 weeks. Both the NC and 
the HFD containing cornstarch or glucoraphanin were prepared by Research Diets. All 
mice studied were maintained on a 12 h light/dark cycle at 24–26°C with free access to 
water and food. All animal procedures were performed in accordance with the Guidelines 
for the Care and Use of Laboratory Animals at Kanazawa University, Japan. 
 
Indirect calorimetry 
 After 3 weeks of feeding, mice were individually housed in an indirect calorimeter 
chamber at 24–26°C (Oxymax; Columbus Instruments, Columbus, OH). Calorimetry, daily 
Page 6 of 60
For Peer Review Only
Diabetes
body weight, and daily food intake data were acquired during a 3-day acclimation period, 
followed by a 2-day experimental period. Oxygen consumption (VO2) and carbon dioxide 
production (VCO2) were measured in each chamber every 20 minutes. The respiratory 
exchange ratio (RER = VCO2/VO2) was calculated using Oxymax software. Energy 
expenditure was calculated as shown below and normalized to the body mass of each 
subject.  
Energy expenditure = VO2 × [3.815 + (1.232 ×RER)] 
 
Metabolic measurements and biochemical analyses 
 Metabolic parameters, body fat composition, insulin sensitivity, and glucose 
tolerance were assessed as previously described (20). Plasma LPS levels were analyzed 
using a Limulus amebocyte lysate assay kit (QCL-1000; Lonza, Allendale, NJ). Plasma 
LPS binding protein (LBP) levels were determined using an ELISA kit (Enzo Life 
Sciences, Farmingdale, NY). Immunoblotting was performed with primary antibodies 
(Supplementary Table 1) as previously described (20). mRNA expression levels were 
determined by quantitative real-time PCR using SYBR Green with the primers 
(Supplementary Table 2) as previously described (20). 
 
Isolation and differentiation of inguinal white adipose tissue-derived primary beige 
adipocytes 
 Stromal vascular fractions (SVFs) from inguinal white adipose tissue (WAT) of 7-
week-old wild-type and Nrf2
-/-
 mice were prepared as previously reported (21). At 
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confluence, SVF cells were induced for 2 days with differentiation medium containing 
DMEM/F-12 supplemented with 10% FBS, 20 nM insulin, 1 nM T3, 5 µM dexamethasone, 
500 µM isobutylmethylxanthine, 125 µM indomethacin, and 0.5 µM rosiglitazone (all from 
Sigma-Aldrich, St. Louis, MO). Induced cells were subsequently cultured in maintenance 
medium (DMEM/F-12 containing 10% FBS, 20 nM insulin, and 1 nM T3) for 5 days and 
treated with DMSO or sulforaphane (Toronto Research Chemicals, Toronto, Canada) at the 
indicated concentrations for 48 h. 
 
Fluorescence-activated cell sorting (FACS) 
 Cells from the liver and epididymal WAT were prepared as previously described 
(22). Isolated cells were incubated with Fc-Block (BD Bioscience, San Jose, CA), and 
subsequently incubated with fluorochrome-conjugated antibodies (Supplementary Table 1). 
Flow cytometry was performed using a FACSAria II (BD Bioscience), and the data were 
analyzed using FlowJo software (Tree Star, Ashland, OR). 
 
Analysis of gut microbiota via pyrosequencing of the 16S rRNA gene 
 Metagenomic DNA was extracted from mouse cecal content with a QIAamp DNA 
stool kit (Qiagen, Hilden, Germany). The V1–V2 region of the 16S rRNA gene was 
amplified using primer sets as previously reported (23). Mixed samples were prepared by 
pooling approximately equal amounts of PCR amplicons from each sample and subjected to 
a GS Junior System (Roche Diagnostics, Basel, Switzerland) for subsequent 454 
sequencing. Pre-processing and taxonomic assignment of sequencing reads were conducted 
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as described previously (23) and separated by unique barcodes. The 16S rRNA sequence 
database was constructed by retrieving 16S sequences of bacterial isolates (1200–2384 
bases in length) from the Ribosomal Database Project Release 10.27. We used 4000 filter-
passed reads of 16S sequences for the operational taxonomic unit (OTU) analysis of each 
sample. Clustering of 16S sequence reads with identity scores > 96% into OTUs was 
performed using UCLUST (www.drive5.com). Representative sequences with identity 
scores > 96% for each OTU were assigned to bacterial species using BLAST. Principal 
component analysis using EZR software (http://www.jichi.ac.jp/saitama-
sct/SaitamaHP.files/statmedEN.html) was applied for assessment of alterations of cecal 
bacterial phylum associated with diets. 
 
Statistical analyses  
 Data were expressed as mean ± SEM. P < 0.05 was considered statistically 
significant. Statistical differences between pairs of groups were determined by a two-tailed 
Student’s t-test. An overall difference between more than two groups was determined using 
a one-way ANOVA. If one-way ANOVAs were significant, differences between individual 
groups were estimated using a Bonferroni post hoc test All calculations were performed 
using SPSS Statistics (v19.0, IBM, Armonk, NY).   
 
Results 
Glucoraphanin decreases weight gain and adiposity, and increases energy expenditure 
in high-fat diet (HFD)-fed mice 
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 To investigate the effects of glucoraphanin on systemic energy balance, we 
examined the body weight of wild-type mice fed normal chow (NC) or a high-fat diet 
(HFD), supplemented with glucoraphanin or vehicle (i.e., cornstarch only). Glucoraphanin 
reduced weight gain only in HFD-fed mice without affecting food intake (Fig. 1A and 
Supplementary Fig. 1A). This reduction was not accompanied by evidence of gross toxicity. 
We determined the plasma concentration of sulforaphane in NC-GR and HFD-GR mice, 
but not in NC or HFD mice, indicating that glucoraphanin was absorbed as a sulforaphane 
following food consumption (Supplementary Fig. 1B). The reduction of weight gain in 
glucoraphanin-treated HFD-fed mice was largely attributed to the decreased fat mass but 
not lean mass (Fig. 1B). To assess energy expenditure, we placed the mice in indirect 
calorimetry cages after 3 weeks of feeding, before an evident change in the body mass of 
HFD-fed mice was observed (HFD: 29.9 ± 0.5 g vs. HFD-GR: 28.5 ± 0.5 g). 
Glucoraphanin-treated mice fed the HFD exhibited consistently higher VO2 and VCO2 than 
vehicle-treated HFD-fed controls (Fig. 1C and D), leading to increased energy expenditure 
(Fig. 1E); however, they displayed similar RER (Fig. 1F), suggesting that glucoraphanin 
supplementation enhanced sugar and fat use under HFD conditions. On NC-fed mice, 
glucoraphanin did not affect these parameters of energy balance (Fig. 1B–F). Consistent 
with increased energy expenditure, glucoraphanin increased the core body temperature of 
HFD-fed mice by approximately 0.5°C (Fig. 1G).  
 
Glucoraphanin improves diet-induced insulin resistance and glucose tolerance 
 After 14 weeks of feeding, glucoraphanin supplementation did not affect plasma 
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triglycerides, total cholesterol, and free fatty acid (FFA) levels in either NC- or HFD-fed 
mice (Table 1). On NC, blood glucose levels were not altered by glucoraphanin, but on the 
HFD, glucoraphanin-treated mice exhibited significantly lower fasted blood glucose 
compared with vehicle-treated controls (Table 1). Additionally, glucoraphanin significantly 
decreased plasma insulin concentrations in HFD-fed mice under both fasted and fed 
conditions, resulting in lower homeostatic model assessment-insulin resistance (HOMA-IR; 
Table 1). During the insulin tolerance test (ITT), glucoraphanin significantly enhanced the 
reduction in blood glucose levels in HFD-fed mice, but not in NC-fed mice compared with 
the vehicle-treated controls (Fig. 2A). Glucoraphanin improved glucose tolerance in HFD-
fed mice during the glucose tolerance test (GTT), but had no effect on NC-fed mice (Fig. 
2B). Insulin secretion during the GTT was not affected by glucoraphanin (data not shown). 
In line with increased insulin sensitivity, insulin-stimulated Akt phosphorylation on Ser
473
 
was enhanced by glucoraphanin in the liver, muscle, and epididymal WAT of mice fed the 
HFD (Fig. 2C).  
 




 Although the Keap1-Nrf2 pathway is a well-known target of sulforaphane, this 
isothiocyanate has also been reported to modulate different biological pathways 
independent of the Keap1-Nrf2 pathway (24,25). To determine whether the anti-obesity and 
insulin-sensitizing effects of glucoraphanin are mediated through Nrf2, the effects of 
glucoraphanin on energy balance and glucose metabolism were assessed in NC- and HFD-
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 mice. Although food intake and plasma concentration of sulforaphane in NC-GR 
or HFD-GR diet-fed Nrf2
-/-
 nice were comparable that detected in wild-type mice fed NC-
GR or HFD-GR diet (Supplementary Fig. 1C and D), the effects of glucoraphanin 
following HFD feeding on weight gain (Fig. 3A), VO2 (Fig. 3B), VCO2 (Fig. 3C), energy 
expenditure (Fig. 3D), RER (Fig. 3E), rectal temperature (Fig. 3F), insulin sensitivity (Fig. 
3G), and glucose tolerance (Fig. 3H) were abolished by the Nrf2 deficiency. These data are 
consistent with comparable plasma metabolic parameters between glucoraphanin-treated 
and vehicle-treated mice on the HFD. These metabolic parameters include lipids, blood 
glucose, insulin, HOMA-IR, and liver enzymes such as alanine transaminase (ALT) and 
aspartate transaminase (AST) (Supplementary Table 3). 
 
Glucoraphanin blocks HFD-induced reduction of Ucp1 expression in WAT of wild-
type mice but not in Nrf2
-/-
 mice 
 The increased energy expenditure and body temperature of glucoraphanin-treated 
HFD-fed mice suggest an increase in adaptive thermogenesis. However, glucoraphanin 
supplementation had little effect on the size and number of lipid droplets in the 
intrascapular brown adipose tissue (BAT) of HFD-fed wild-type mice (Supplementary Fig. 
2A). In addition, the mRNA expression of uncoupling proteins (Ucps), PGC-1α, and 
deiodinase 2 in BAT and of Ucps in skeletal muscle was not altered by glucoraphanin 
supplementation in both NC- and HFD-fed wild-type mice (Supplementary Fig. 2B and C). 
In BAT, HFD increased Ucp1 protein expression, but glucoraphanin did not alter the 
expression in both wild-type and Nrf2
-/-
 mice (Fig. 4A). Brown-like adipocytes expressing 
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Ucp1, also known as beige cells, exist in various WAT depots and can contribute to 
thermogenesis (26). Compared with NC, HFD significantly decreased Ucp1 protein levels 
in epididymal and inguinal WAT of both wild-type and Nrf2
-/-
 mice (Fig. 4A). 
Glucoraphanin supplementation restored HFD-induced reduction in Ucp1 protein levels in 
epididymal and inguinal WAT of wild-type mice but not those in Nrf2
-/-
 mice. To examine 
whether the effects of glucoraphanin were fat cell-autonomous and Nrf2-mediated, we 
tested the effects of sulforaphane, an active metabolite of glucoraphanin, on the expression 
of brown fat-selective genes in primary beige adipocytes obtained from inguinal WAT of 
wild-type and Nrf2
-/-
 mice. In beige adipocytes derived from wild-type mice, treatment with 
sulforaphane induced the Nrf2 target gene, NAD(P)H:quinone oxidoreductase 1 (Nqo1; 
Fig. 4B) and antioxidant genes (Supplementary Fig. 3A). Concurrently, sulforaphane 
significantly increased the mRNA expression of brown-fat selective genes, including Ucp1, 
Prdm16, Cidea, and Elovl3 (Fig. 4B). In contrast, in Nrf2-deficient beige adipocytes, 
sulforaphane failed to activate Nrf2 as judged by unaltered mRNA expression of the target 
genes and to promote the expression of brown-fat selective genes (Supplementary Fig. 3B 
and Fig. 4C). Importantly, Nrf2-deficient beige adipocytes exhibited less differentiation 
levels associated with attenuated lipid accumulation (Supplementary Fig. 3C) and lower 
mRNA expression of fatty acid binding protein 4 (Supplementary Fig. 3C) and brown-fat 
selective genes compared with wild-type beige adipocytes (Fig. 4C). 
 
Glucoraphanin reduces hepatic steatosis and oxidative stress in HFD-fed mice  
 The HFD causes hepatic steatosis and inflammation, eventually leading to 
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steatohepatitis. As shown in Fig. 5A, the increase in liver weight caused by the 14-week-
HFD was alleviated by glucoraphanin supplementation. Glucoraphanin also attenuated 
HFD-induced hepatic steatosis (Fig. 5B). Additionally, compared with the HFD group, the 
lower levels of plasma ALT, plasma AST, liver triglycerides, and liver FFAs in the HFD-
GR group indicate that glucoraphanin alleviated HFD-induced liver damage (Fig. 5C and 
D). The reduction in hepatic steatosis was accompanied by the decreased expression of the 
following lipogenic genes: sterol regulatory element binding protein-1c (Srebf1), fatty acid 
synthase (Fasn), and peroxisome proliferator-activated receptor gamma (Pparγ) (Fig. 5E). 
Additionally, hepatic levels of malondialdehyde, a marker of lipid peroxidation, were 
increased by the HFD. Glucoraphanin attenuated lipid peroxidation (Fig. 5F) and decreased 









(Fig. 5E). The HFD led to a compensatory increase in the expression of genes involved in 
fatty acid β-oxidation (Ppara and Cpt1a) and anti-oxidative stress (Cat, Gpx1, and Sod1) in 
the liver. However, glucoraphanin did not increase the expression of these genes in the liver 
of HFD-fed mice further (Fig. 5E).  
 
Glucoraphanin suppresses HFD-induced proinflammatory activation of macrophages 
in liver and adipose tissue 
 In response to the HFD, liver-resident macrophages (Kupffer cells) increase the 
production of proinflammatory cytokines that promote insulin resistance and NAFLD in 
mice (27). In particular, chemokine (C-C motif) ligand 2 (Ccl2) promotes the recruitment 
of chemokine (C-C motif) receptor 2 (Ccr2)-positive monocytic lineages of myeloid cells 
Page 14 of 60
For Peer Review Only
Diabetes
into the liver (28). These recruited cells produce a large amount of proinflammatory 
mediators and activate a lipogenic program (28). Here, we found a prominent induction of 
tumor necrosis factor-α (Tnf-α), Ccl2, and Ccr2 in the liver of HFD-fed mice, which was 
markedly reduced in glucoraphanin-treated mice (Fig. 6A). Glucoraphanin significantly 
suppressed HFD-induced inflammatory pathways such as c-Jun N-terminal kinase (JNK) 
and extracellular signal-regulated kinase (Erk) (Fig. 6B). Glucoraphanin tended to decrease 
levels of p-NF-κB p65 (Ser
536
) in HFD-fed mice, although this decrease was not 
statistically significant (Fig. 6B). Of note, in the liver of Nrf2
-/-
 mice, glucoraphanin failed 
to suppress HFD-induced inflammatory signal pathways (Supplementary Fig. 4). In 
addition, glucoraphanin significantly decreased the HFD-induced hepatic expression of 
macrophage markers, including F4/80, Cd11b, and Cd68 (Fig. 6C). Tissue macrophages are 
phenotypically heterogeneous and have been characterized according to their 
activation/polarization state as M1-like proinflammatory macrophages or M2-like anti-
inflammatory macrophages (29). Consistent with the decreased expression of macrophage 




 cell) accumulation in the 
liver of HFD-fed mice (Fig. 6D). Additionally, glucoraphanin decreased the number of M1-


















), resulting in a predominantly M2-like macrophage 
population (Fig. 6E). Moreover, glucoraphanin decreased the mRNA expression of Tnf-α 
and NADPH oxidase in the epididymal WAT of HFD-fed mice (Supplementary Fig. 5A). 
Although the HFD-induced expression of macrophage markers and macrophage 
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accumulation in epididymal WAT were not altered by glucoraphanin (Supplementary Fig. 
5B and C), the number of M1-like macrophages was significantly decreased in the 
epididymal WAT of glucoraphanin-treated HFD-fed mice (Supplementary Fig. 5D).  
 
Glucoraphanin decreases circulating LPS and the relative abundance of 
Proteobacteria in the gut microbiomes of HFD-fed mice 
 Gut microbiota-derived LPS induces chronic inflammation that eventually leads to 
insulin resistance in obesity, termed metabolic endotoxemia (1,2). Based on our observation 
that glucoraphanin alleviates inflammation in the liver and epididymal WAT of HFD-fed 
mice, we subsequently investigated the effects of glucoraphanin on metabolic endotoxemia 
and gut microbiota. In accordance with previous studies (1,2), the HFD induced a 2-fold 
increase in circulatory LPS levels, which was reduced by glucoraphanin supplementation 
(Fig. 7A). Furthermore, plasma and hepatic levels of the LPS marker, LBP, were 
significantly elevated by the HFD and were reduced by glucoraphanin supplementation 
(Fig. 7B). A principal component analysis distinguished cecal microbial communities based 
on diet and treatment, revealing that the metagenomes of HFD-fed mice formed a cluster 
distinct from the cluster formed by NC-fed mice (Fig. 7C). However, samples from 
glucoraphanin-treated HFD-fed mice formed a cluster that was indistinguishable from that 
of vehicle- or glucoraphanin-treated NC-fed mice (Fig. 7C). Importantly, consistent with 
previous reports (30,31), further analysis at the phylum level demonstrated that the 
proportion of Gram-negative Proteobacteria was significantly elevated in the gut 
microbiomes of HFD-fed mice, which was suppressed by glucoraphanin supplementation 
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(Fig. 7D and E). The increase in the relative abundance of Proteobacteria in HFD-fed mice 
is mostly explained by an increase in the relative abundance of bacteria from the family 
Desulfovibrionaceae (Fig. 7F), key producers of endotoxins in animal models of obesity 
(30). In fact, the relative abundance of Desulfovibrionaceae was positively correlated with 
plasma LPS levels (Fig. 7G). Furthermore, plasma LPS levels were significantly and 
positively correlated with the hepatic mRNA levels of Tnf-α, gp91
phox
, and F4/80 (Fig. 7H). 
Similarly, the liver expression of other marker genes was both significantly and positively 
correlated with plasma LPS levels and with one another (Supplementary Table 4).  
 
Discussion 
 In the present study, we demonstrated that glucoraphanin, a stable precursor of the 
Nrf2 inducer sulforaphane, mitigated HFD-induced weight gain, insulin resistance, hepatic 
steatosis, oxidative stress, and chronic inflammation in mice. The weight-reducing and 
insulin-sensitizing effects of glucoraphanin were abolished in Nrf2
-/-
 mice. Additionally, 
glucoraphanin lowered plasma LPS levels in HFD-fed mice, and decreased the relative 
abundance of Desulfovibrionaceae. At the molecular level, glucoraphanin increased Ucp1 
protein expression in WAT depots, while suppressing the hepatic mRNA expression of 
genes involved in lipogenesis, NADPH oxidase, and inflammatory cytokines. Our data 
suggest that in diet-induced obese mice, glucoraphanin restores energy expenditure and 
limits gut-derived metabolic endotoxemia, thereby preventing hepatic steatosis, insulin 
resistance, and chronic inflammation.  
 Consistent with previous reports demonstrating the anti-obesity effects of synthetic 
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Nrf2 inducers (9–11), we show that the oral administration of glucoraphanin mitigates 
HFD-induced weight gain (Fig. 1A). The dose of glucoraphanin used in the current study 
(about 12 µmol/mouse/day) is similar to that used in other experiments investigating its 
antitumor effects in mice (14,32,33). Here, we show that the effect of glucoraphanin on 
whole-body energy expenditure and the protein expression of Ucp1 in WAT were abolished 
in Nrf2
-/-
 mice (Fig. 3D and 4A). A recent study using adipocyte-specific PRDM16-
deficient mice indicated that adaptive thermogenesis in beige fat also contributes to 
systemic energy expenditure (26). The mutant mice in the aforementioned study, which 
exhibited markedly reduced Ucp1 mRNA expression in inguinal WAT and minimal effects 
on BAT, developed obesity and insulin resistance in response to a HFD. Thus, we believe 
that the increased energy expenditure in glucoraphanin-treated HFD-fed mice stems from, 
at least in part, an increase in beige fat, even though the expression of Ucps in BAT and 
skeletal muscle is not altered. Further analysis using Ucp1-knockout mice will elucidate the 
relative contribution of beige fat to the Nrf2-mediated metabolic effects elicited by 
glucoraphanin. 
 Several studies indicated that Nrf2
-/-
 mice are partially protected from HFD-induced 
obesity and associated with milder insulin resistance compared with wild-type counterparts 
(9,34,35). Recently, Schneider et al. demonstrated that mitigation of HFD-induced obesity 
in Nrf2
-/-
 mice, which was 25% less body weight than that of wild-type mice after 6 weeks 
of feeding (35). They also found that HFD-fed Nrf2
-/-
 mice exhibit a 20–30% increase in 
energy expenditure that is associated with an approximately 3-fold up-regulation of Ucp1 
protein expression in abdominal WAT (35). In the present study, Nrf2
-/-
 mice gained less 
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weight after 6 weeks of HFD feeding compared with HFD-fed wild-type mice (Figure 1A 
and 3A; Nrf2
-/-
: 35.9 ± 0.9 g vs. wild-type: 39.0 ± 0.8 g, P < 0.05). The lower body mass of 
Nrf2
-/-
 mice raises the possibility that anti-obesity effect of glucoraphanin was completely 
phenocopied by Nrf2 gene deficiency. However, several observations suggest that Nrf2
-/-
 
mice only partially phenocopy the effect of glucoraphanin on weight gain reduction. 1) In 
the present study, the weight difference between Nrf2
-/-
 and wild-type mice was only 8%, 
which is much less than that in the previous study (35). 2) In Nrf2
-/-
 mice, compared with 
NC, HFD induced significant weight gain (Fig. 3A), glucose intolerance (Fig. 3H), and 
insulin resistance as judged by increased HOMA-IR (Supplementary Table 3). 3) Metabolic 
rate and energy expenditure of Nrf2
-/-
 mice were comparable with those in wild-type mice 
(Fig. 1C–E and 3B–D). 4) Ucp1 protein levels in both epididymal WAT and inguinal WAT 
of HFD-fed Nrf2
-/-
 mice were lower than those in HFD-GR-fed wild-type mice (Fig. 4A). 
Taken together, these findings suggest that Nrf2 gene deficiency is not sufficient to block 
HFD-induced obesity by increasing energy expenditure and Ucp1 expression in WAT 
depots, and to mask the effect of glucoraphanin. However, we cannot fully exclude the 
possibility that the effects of glucoraphanin are mediated by Nrf2 independent-mechanisms. 
Possible reasons for the discordance in metabolic phenotypes of Nrf2
-/-
 between the 
previous study (35) and ours may be due to differences in knockout mouse lines and 
experimental conditions (e.g. age of mice at beginning of HFD feeding, composition of 
HFD, and temperature in the metabolic chamber).  
Our in vitro study of primary beige adipocytes revealed that sulforaphane promotes the 
expression of brown-fat selective genes (Fig. 4B). Importantly, the concentration of 
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sulforaphane used in cell culture (0.2–5 µM) is comparable with that detected in mice fed 
NC-GR and HFD-GR diet (Supplementary Fig. 1B). Moreover, we determined that Nrf2 
acts as a positive regulator of beige adipocyte differentiation (Fig. 4C and Supplementary 
Fig. 3C). The less differentiation levels in Nrf2-deficient beige adipocytes are in agreement 
with previous reports demonstrating Nrf2 induces white adipocyte differentiation through 
increasing the gene expression of Pparγ (34) and Cebpβ (36), common transcription factors 
regulating the differentiation of brown, beige, and white adipocytes. Furthermore, it is 
noteworthy that Nrf2 has been reported to bind NF-E2-binding sites in the 5′-flanking 
region of the human and rodent Ucp1 genes (37). However, we cannot exclude the 
possibilities that glucoraphanin affects sympathetic nervous activity or that hormonal 
factors are regulating fat browning (38). In addition, mitochondrial reactive oxidative 
species facilitate Ucp1-dependent respiration in BAT and whole-body energy expenditure 
by promoting the sulfenylation of a specific cysteine residue (Cys253) in Ucp1 (39). The 
molecular mechanism by which Nrf2 regulates the expression and thermogenic activity of 
Ucp1 in beige adipocytes requires further investigation.  
 Glucoraphanin supplementation improved the systemic glucose tolerance and 
insulin sensitivity of HFD-fed mice. Although the molecular mechanism by which synthetic 
Nrf2 inducers enhance glucose uptake is unclear, AMP-activated protein kinase (AMPK) 
activation may mediate this enhancement in mouse skeletal muscle and adipose tissue (9–
11). The phosphorylation levels of AMPK (Thr
172
) and acetyl-CoA carboxylase (Ser
79
) in 
peripheral insulin target tissues were comparable between glucoraphanin-treated NC- and 
HFD-fed mice and vehicle-treated controls (Supplementary Fig. 6). These data suggest that 
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AMPK activation is not necessary for glucoraphanin to exert its insulin-sensitizing effect 
on HFD-fed mice. Additional studies using the hyperinsulinemic-euglycemic clamp 
technique are needed to determine which tissues contribute to the insulin-sensitizing effects 
of glucoraphanin.  
 The beneficial effects of glucoraphanin on hepatic lipid metabolism were not 
accompanied by AMPK activation or the increased expression of fatty acid β-oxidation 
genes (Fig. 5E). Instead, glucoraphanin mitigated HFD-induced oxidative stress and 
inflammation in the liver. In obesity, hepatic inflammation mediated by 
macrophage/monocyte-derived proinflammatory cytokines promotes lipogenesis through 
the inhibition of insulin signaling and SREBP activation (40,41). In fact, the depletion of 
Kupffer cells by clodronate liposomes ameliorates hepatic steatosis and insulin sensitivity 
in HFD-fed mice (27). Furthermore, Ccl2- or Ccr2-deficient mice are protected from diet-
induced hepatic steatosis even though they still become obese (42,43). Moreover, the 
specific ablation of M1-like macrophages restores insulin sensitivity in diet-induced obese 
mice (44), while the deletion of Pparδ, which promotes M2 activation, predisposes lean 
mice to develop insulin resistance (45). Therefore, decreased hepatic macrophage 
accumulation and M2-dominant polarization of hepatic and adipose macrophages account, 
at least in part, for the protection from hepatic steatosis and insulin resistance in 
glucoraphanin-treated HFD-fed mice. 
 One of the most important findings of this study is that glucoraphanin decreases the 
relative abundance of Gram-negative Proteobacteria, particularly family 
Desulfovibrionaceae, while reducing circulatory LPS levels (Fig. 7). Recent studies 
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demonstrated that a significant increase in Desulfovibrionaceae, potential endotoxin 
producers, in the gut microbiomes of both HFD-induced obese mice and obese human 
subjects compared to lean individuals (30,31,46). We cannot exclude the possibility that 
other microbiota-derived products, such as bile acids and short chain fatty acids, also 
mediate the metabolic action of glucoraphanin. Whether the interaction between 
sulforaphane and gut microbiota is affected directly or indirectly by altered host physiology 
remains to be determined. However, several studies have suggested that sulforaphane can 
alter the gut microbiota directly, as isothiocyanates (including sulforaphane) have been 
shown to exhibit antibacterial activity against Proteobacteria (47,48). This activity may 
proceed via redox disruption and enzyme denaturation reactions involving the 
isothiocyanate reactive group, -N=C=S, the thiol group (-SH) of glutathione and 
proteobacterial proteins (47,48). Additionally, sulforaphane exhibits antibacterial activity 
against Helicobacter pylori, a member of the phylum Proteobacteria (49). We are unaware 
of any previous reports demonstrating that isothiocyanates inhibit the proliferation of 
Desulfovibrionaceae. The mechanistic underpinnings of this antibacterial activity require 
elucidation. 
 In conclusion, the results of the present study indicate that glucoraphanin may be 
effective in preventing obesity and related metabolic disorders such as NAFLD and type 2 
diabetes. A recent clinical study demonstrated that supplementation with a dietary dose of 
glucoraphanin (69 µmol/day) for two months significantly decreased the plasma liver 
enzymes, ALT and AST, although body mass did not change (18). Long-term treatment 
with a higher dose of glucoraphanin (800 µmol/day), which can be safely administered 
Page 22 of 60
For Peer Review Only
Diabetes
without any harmful side effects (17), may be required to achieve an anti-obesity effect in 
humans. 
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Table 1 Metabolic parameters in fed and fasted mice 
 
NC NC-GR HFD HFD-GR 
Plasma TG (mg/dL) 139.2 ± 9.4 140.7 ± 8.1 144.6 ± 5.4 123.6 ± 9.2 
Plasma TC (mg/dL) 161.2 ± 7.7 161.4 ± 3.5 212.6 ± 2.1** 210.2 ± 1.8** 
Plasma FFAs (mmol/L) 0.85 ± 0.07 0.96 ± 0.07 0.93 ± 0.05 0.81 ± 0.05 
Blood glucose (mg/dL) 
    
Fed 126 ± 6 124 ± 3 152 ± 4** 145 ± 4* 
Fasted 77 ± 3 76 ± 3 131 ± 9** 94 ± 5## 
Plasma insulin (ng/mL) 
    
Fed 1.4 ± 0.2 1.0 ± 0.2 5.3 ± 0.5** 3.6 ± 0.4**# 
Fasted 0.2 ± 0.0 0.1 ± 0.0 2.2 ± 0.2** 1.3 ± 0.2**## 
HOMA-IR 1.0 ± 0.1 0.6 ± 0.2 17.7 ± 1.6** 8.0 ± 1.3**## 
Shown are blood glucose and plasma insulin levels of mice fed (ad libitum) or fasted for 16 
h. Plasma triglyceride (TG), total cholesterol (TC), and free fatty acids (FFAs) were 
measured in fasting plasma. Measurements are reported as mean ± SEM (n = 9/group). *P 
< 0.05, **P < 0.01 vs. NC; #P < 0.05, ##P < 0.01 vs. HFD. NC: normal chow, HFD: high-
fat diet, GR: glucoraphanin, HOMA-IR: homeostasis model assessment of insulin 
resistance. 
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Figure 1—Glucoraphanin reduces weight gain and increases energy expenditure in high-fat 
diet (HFD)-fed mice. A: Body weight of mice fed normal chow (NC; white circles), chow 
with glucoraphanin (NC-GR; black circles), a high-fat diet (HFD; white triangles), or HFD 
with glucoraphanin (HFD-GR; black triangles) (n = 9/group). B: Representative computed 
tomographic images of abdominal regions of mice fed the indicated diet for 13 weeks. Pink 
and yellow areas represent visceral and subcutaneous fat, respectively. Bar graphs represent 
body fat mass and lean mass calculated from the CT scan data. Oxygen consumption (C; 
VO2), carbon dioxide production (D; VCO2), energy expenditure (E), and respiratory 
exchange ratio (F; RER) during light and dark cycles in mice fed the indicated diet for 3 
weeks. G: Rectal temperature in mice fed the indicated diet for 6 weeks. Data are presented 
as mean ± SEM. *P < 0.05, **P < 0.01 vs. NC; #P < 0.05, ##P < 0.01 vs. HFD.  
 
Figure 2—Glucoraphanin improves insulin sensitivity and glucose tolerance in HFD-fed 
mice. A: Insulin tolerance test (ITT, 0.9 U/kg body weight for NC and NC-GR mice; 1.2 
U/kg body weight for HFD and HFD-GR mice) after 11 weeks of feeding (n = 9/group). B: 
Glucose tolerance test (GTT, 2 g/kg body weight) after 9 weeks (n = 9/group). Bar graphs 
represent AUC calculations. C: Mice on the indicated diet for 14 weeks were injected 
intraperitoneally with saline (n = 2/group) or insulin (n = 6/group, 10 U/kg body weight), 
and sacrificed 10 min after injection. Total liver, quadriceps muscle, and epididymal 
adipose depot (eWAT) lysates were immunoblotted for pS473-Akt and Akt, quantitated, 
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and presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. NC; #P < 0.05, ##P < 0.01 vs. 
HFD. A.U.: arbitrary unit. 
 
Figure 3—The anti-obesity and insulin sensitizing effects of glucoraphanin are abolished 
in Nrf2
-/-
 mice. A: Body weight of Nrf2
-/-
 mice fed normal chow (NC; white circles), chow 
with glucoraphanin (NC-GR; black circles), a high-fat diet (HFD; white triangles), or HFD 
with glucoraphanin (HFD-GR; black triangles) for 14 weeks. VO2 (B), VCO2 (C), energy 
expenditure (D), respiratory exchange ratio (E; RER) of Nrf2
−/−
 mice fed the indicated diet 
for 3 weeks. F: Rectal temperature in mice Nrf2
-/-
 fed the indicated diet for 6 weeks. ITT 
(0.9 U/kg body weight for NC and NC-GR mice; 1.2 U/kg body weight for HFD and HFD-
GR mice) (G) and GTT (2 g/kg body weight) (H) were performed after 9 and 11 weeks of 
feeding, respectively. Bar graphs represent AUC calculations. Data are presented as mean ± 
SEM (NC: n = 8, NC-GR: n = 8, HFD: n = 10, HFD-GR: n = 8). *P < 0.05, **P < 0.01 vs. 
NC. 
 
Figure 4—Glucoraphanin blocks HFD-induced reduction of uncoupling protein-1 (Ucp1) 
protein levels in white adipose depots of wild-type mice but not in Nrf2-knockout (Nrf2
-/-
) 
mice. A: Shown are immunoblot analyses of Ucp1 and Tubulin expression using lysates of 
brown adipose tissue (BAT; 0.5 µg protein), epididymal fat depots (eWAT; 5 µg protein), 
and inguinal fat depots (ingWAT; 2 µg protein) from wild-type or Nrf2
-/-
 mice on the 
indicated diet for 14 weeks. Bar graphs represent normalized data of Ucp1/Tubulin from 
four independent blots, and are presented as mean ± SEM (n = 8/group). *P < 0.05, **P < 
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0.01 vs. NC-fed wild-type or NC-fed Nrf2
-/-
 mice; ##P < 0.01 vs. HFD-fed wild-type mice. 
B: Quantitative real-time PCR determination of mRNA levels of Nqo1 and of genes 
involved in fat browning in the absence or presence of sulforaphane (SFN; 0.2, 1, 2, or 5 
µM) in primary beige adipocytes isolated from inguinal WAT of wild-type mice 
(normalized against 36B4). Bar graphs represent mean ± SEM (n = 6/group). C: The same 
experiment as in (B) was repeated with primary beige adipocytes isolated from ingWAT of 
Nrf2
-/-
 mice. *P < 0.05, **P < 0.01 vs. DMSO-treated wild-type adipocytes. The difference 
was determined using a one-way ANOVA. Post hoc analysis was performed using 
Dunnett’s test. Prdm16: PR domain containing 16, Cidea: cell death-inducing DFFA-like 
effector A, Elovl3: fatty acid elongase 3. 
 
Figure 5—Glucoraphanin alleviates HFD-induced hepatic steatosis and oxidative stress. A: 
Livers of mice fed the indicated diet for 14 weeks. Scale bar, 100 mm. Bar graphs represent 
the liver weights (n = 9/group). B: H&E staining (original magnification, ×200; scale bars, 
100 µm). C: Plasma ALT (left panel) and AST levels (right panel). D: Liver triglyceride 
(left panel) and FFA content (right panel). E: Quantitative real-time PCR determination of 
hepatic mRNA expression of genes involved in fatty acid synthesis, NADPH oxidase 
complex, antioxidant stress response, and fatty acid β-oxidation (normalized against 36B4). 
F: Hepatic levels of malondialdehyde. Results represent mean ± SEM. *P < 0.05, **P < 
0.01 vs. NC; #P < 0.05, ##P < 0.01 vs. HFD. ALT: alanine transaminase, AST: aspartate 
transaminase, TG: triglyceride, FFAs: free fatty acids, Cat: catalase, Gpx1: glutathione 
peroxidase 1, Sod1: superoxide dismutase 1, Ppara: peroxisome proliferator-activated 
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receptor α, Cpt1a: carnitine palmitoyltransferase 1a. 
 
Figure 6—Glucoraphanin improves liver inflammation in HFD-fed mice. A: Relative 
mRNA expression of tumor necrosis factor-α (Tnf-α), chemokine (C-C motif) ligand 2 
(Ccl2), and chemokine (C-C motif) receptor 2 (Ccr2) in the liver of mice fed the indicated 









), Erk, p-NF-κB p65 (Ser
536
), and NF-κB p65 using liver lysates. Each 
lane represents a liver lysate from a different animal (n = 8/group). Bar graphs represent 
normalized data of p-JNK/JNK, p-Erk/Erk, and p-NF-κB p65/NF-κB p65 from two 
independent experiments, presented as mean ± SEM. C: Relative mRNA expression of 
macrophage markers. D: FACS analysis of macrophages in the liver of mice fed a HFD or 














 cells. Bar graph shows the number of liver 









, respectively. Bar graphs show the percentage of M1- and M2-like 
macrophages, and the M1/M2 ratio. Data are presented as mean ± SEM. *P < 0.05, **P < 
0.01 vs. NC; #P < 0.05, ##P < 0.01 vs. HFD. A.U.: arbitrary unit.  
 
Figure 7—Glucoraphanin decreases circulating lipopolysaccharide (LPS) and Gram-
negative Proteobacteria in the gut microbiomes of HFD-fed mice. A: Plasma levels of LPS 
and LPS binding protein (LBP; B, left panel) in mice fed the indicated diet for 14 weeks (n 
= 6–7/group). Hepatic mRNA levels of Lbp (B, right panel) were determined by 
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quantitative RT-PCR. C: A principal component analysis was performed using the phylum-
level taxonomic profiles of the cecal microbiota of the mice. Each plot represents the 
taxonomic profile data of individual mice. White circles = NC; white triangles = NC-GR; 
black circles = HFD; black triangles = HFD-GR. The closer the spatial distance between 
the individual data, the more similar they are with respect to both axes (PC1 and PC2). D: 
Relative abundance distribution of operational taxonomic unit (OTU) sequences (96% 
level). Percentage of total OTU sequences taxonomically assigned to bacterial phyla from 
cecal contents of mice fed the abovementioned diets for 14 weeks. E: Relative abundance 
of OTU sequences assigned to Proteobacteria phyla are shown as box plots. F: Relative 
abundance of OTU sequences assigned to Desulfovibrionaceae family is shown as box 
plots. Data are presented as mean ± SEM (n = 6–7/group). *P < 0.05, **P < 0.01 vs. NC; 
#P < 0.05 vs. HFD. G: Plasma LPS levels plotted against the relative abundance of the 
Desulfovibrionaceae family in the cecal contents. H: Correlations between plasma LPS and 
hepatic mRNA expression levels of TNF-α, gp91
phox
, and F4/80. Inset corresponds to 
Spearman’s r correlation and corresponding P value.  
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Akt Cell Signaling Technology #9271 
Akt Cell Signaling Technology #9272 
pS
79
-ACC Cell Signaling Technology #3661 
ACC Cell Signaling Technology #3662 
pT
172
-AMPKα Cell Signaling Technology #2531 





Erk1/2 Cell Signaling Technology #9101 





JNK Cell Signaling Technology #9255 
JNK Cell Signaling Technology #9258 
pS
536
NF-κB p65 Cell Signaling Technology #3033 
NF-κB p65 Cell Signaling Technology #3034 
Tubulin  Cell Signaling Technology #2128 
Ucp1 Abcam ab10983 
PerCP-Cyanine5.5-conjugated NK1.1 eBioscience #45-5941 
PerCP-Cyanine5.5-conjugated CD3 eBioscience #45-036 
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PerCP-Cyanine5.5-conjugated CD19 eBioscience #45-0193 
PerCP-Cyanine5.5-conjugated TER-119 eBioscience #45-5921 
Allophycocyanin-eFluor 780-conjugated CD45 eBioscience #47-0451 
Phycoerythrin-conjugated CD11c eBioscience #12-0114 
eFluor 450-conjugated Ly-6G (Gr-1) eBioscience #48-5931 
PE/Cy7-conjugated F4/80 Biolegend #123113 
Alexa Fluor 647-conjugated CD206 Biolegend #141712 
PE-Texas Red-conjugated CD11b Invitrogen #RM2817 
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Supplementary Table 2: Primers used for quantitative RT-PCR.  
Gene/Primer Forward Reverse 
Catalase CCAGCGACCAGATGAAGCAG  CCACTCTCTCAGGAATCCGC 
Ccl2 AGGTCCCTGTCATGCTTCTGG CTGCTGCTGGTGATCCTCTTG 
Ccr2 ATTCTCCACACCCTGTTTCG GATTCCTGGAAGGTGGTCAA 
CD11b CATCAAGGGCAGCCAGATTG GAGGCAAGGGACACACTGAC 
CD11c AAAATCTCCAACCCATGCTG CACCACCAGGGTCTTCAAGT 
CD68 CTTCCCACAGGCAGCACAG AATGATGAGAGGCAGCAAGAGG 
Cidea TGCTCTTCTGTATCGCCCAGT GCCGTGTTAAGGAATCTGCTG 
Cpt1a AAACCCACCAGGCTACAGTG TCCTTGTAATGTGCGAGCTG 
Dio2 CTTCTGAGCCGCTCCAAGTC CACCCAGTTTAACCTGTTTGTAGG 
Elovl3 TCCGCGTTCTCATGTAGGTCT GGACCTGATGCAACCCTATGA 
F4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
Fasn AGAGACGTGTCACTCCTGGACTT GCTGCGGAAACTTCAGAAAAT 
Fabp4 GGGGCCAGGCTTCTATTCC GGAGCTGGGTTAGGTATGGG 
gp91
phox
 TTGGGTCAGCACTGGCTCTG TGGCGGTGTGCAGTGCTATC  
Gpx1 TTCGGACACCAGGAGAATGG  TAAAGAGCGGGTGAGCCTTC  
Hmox1 CAGAGCCGTCTCGAGCATAG CAAATCCTGGGGCATGCTGT 
Page 45 of 60
For Peer Review Only
Diabetes
Lbp GTCCTGGGAATCTGTCCTTG CCGGTAACCTTGCTGTTGTT 
Nqo1 CTCTGGCCGATTCAGAGTGG CTCCCAGACGGTTTCCAGAC 
p22
phox
 GTCCACCATGGAGCGATGTG  CAATGGCCAAGCAGACGGTC 
p47
phox
 GATGTTCCCCATTGAGGCCG  GTTTCAGGTCATCAGGCCGC  
p67
phox
 CTGGCTGAGGCCATCAGACT  AGGCCACTGCAGAGTGCTTG  
Pparα GAGGGTTGAGCTCAGTCAGG GGTCACCTACGAGTGGCATT 
Pparγ GAAACTCTGGGAGATTCTCCT CAGAGCTGATTCCGAAGTTGG 
Ppargc1a ATGTGTCGCCTTCTTGCTCT ATCTACTGCCTGGGGACCTT 
Prdm16 CAGCACGGTGAAGCCATTC GCGTGCATCCGCTTGTG 
Prdx1 TGTCCCACGGAGATCATTGC GGGTGTGTTAATCCATGCCAG 
Sod1 CAGCATGGGTTCCACGTCCA CACATTGGCCACACCGTCCT 
Srebf1 GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT 
Tnfa CCCACACCGTCAGCCGATTT GTCTAAGTACTTGGGCAGATTGACC 
Ucp1 ACTGCCACACCTCCAGTCATT CTTTGCCTCACTCAGGATTGG 
Ucp2 ATGGTTGGTTTCAAGGCCACA  CGGTATCCAGAGGGAAAGTGAT 
Ucp3 CTGCACCGCCAGATGAGTTT  ATCATGGCTTGAAATCGGACC  
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Supplementary Table 3: Metabolic parameters of Nrf2
-/-
 mice. 
Shown are blood glucose and plasma insulin levels of mice fed (ad libitum) or fasted for 16 
h. Plasma triglyceride (TG), total cholesterol (TC), and free fatty acids (FFAs) were 
measured in fasting plasma. Measurements are reported as mean ± SEM. *P < 0.05, **P < 
0.01 vs. NC. NC: normal chow, HFD: high-fat diet, GR: glucoraphanin, HOMA-IR: 
homeostasis model assessment of insulin resistance, ALT: alanine transaminase, AST: 
 NC (n = 8) NC-GR (n = 8) HFD (n = 11) HFD-GR (n = 7) 
Plasma TG (mg/dL) 99 ± 11 102 ± 11 114 ± 11 131 ± 15 
Plasma TC (mg/dL) 143 ± 25 152 ± 23 187 ± 18 199 ± 21 
Plasma FFAs (mmol/L) 1.4 ± 0.1 1.3 ± 0.1 1.1 ± 0.1* 1.0 ± 0.1** 
Blood glucose (mg/dL) 
      Fed 
Fasted 
Plasma insulin (ng/mL) 
       Fed 
Fasted 
HOMA-IR 
Plasma ALT (IU/L) 
Plasma AST (IU/L) 
 
158 ± 7 
65 ± 3 
 
2.2 ± 0.3 
0.5 ± 0.1 
2.0 ± 0.4 
14.5 ± 1.8 
52.7 ± 4.2 
 
161 ± 6 
68 ± 4 
 
2.1 ± 0.3 
0.5 ± 0.1 
2.0 ± 0.5 
13.8 ± 2.0 
50.2 ± 3.9 
 
191 ± 8** 
100 ± 6** 
 
9.6 ± 2.5 
1.3 ± 0.1** 
9.2 ± 1.1** 
47.8 ± 6.6** 
105.4 ± 9.0** 
 
176 ± 6 
98 ± 5** 
 
7.2 ± 2.1 
1.7 ± 0.2** 
10.7 ± 1.7** 
44.7 ± 4.7** 
105.1 ± 15.4** 
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aspartate transaminase.
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Supplemental Table 4: Metabolic endotoxemia positively correlated with mRNA expression of genes involved in inflammation, 
oxidative stress, and macrophage infiltration in the liver.                                             
  Inflammation Oxidative stress Macrophage infiltration 
 








 F4/80 Cd11b Cd68 
LPS 1            
Tnf-α 0.44* 1           
Il-1β 0.47* 0.55** 1          
Ccl2 0.64** 0.76** 0.54** 1         
Ccr2 0.55** 0.56** 0.65** 0.75** 1        
gp91
phox
 0.59** 0.66** 0.74** 0.80** 0.69** 1       
p22
phox
 0.47* 0.70** 0.64** 0.72** 0.53* 0.94** 1      
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 0.58** 0.61** 0.84** 0.55** 0.58** 0.89** 0.86** 1     
p67
phox
 0.65** 0.67** 0.72** 0.72** 0.69** 0.83** 0.87** 0.85** 1    
F4/80 0.51* 0.53** 0.67** 0.51* 0.51* 0.85** 0.90** 0.87** 0.81** 1   
Cd11b 0.57** 0.60** 0.60** 0.70** 0.50* 0.88** 0.84** 0.71** 0.77** 0.78** 1  
Cd68 0.53* 0.68** 0.64** 0.79** 0.50* 0.91** 0.90** 0.67** 0.69** 0.63** 0.90** 1 
Values correspond to Spearman’s r correlation. *P < 0.05, ** P < 0.01 
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 Supplementary Figure 1—A: Food intake of wild-type mice fed normal chow (NC), 
chow with glucoraphanin (NC-GR), a high-fat diet (HFD), or HFD with GR (HFD-GR) 
was measured after 3 weeks of feeding. Data are presented as the mean ± SEM (n = 
9/group). B: Plasma concentration of sulforaphane in wild-type mice fed the indicated 
diet for 6 weeks. Data are presented as the mean ± SEM (n = 3/group). C: Food intake 
of Nrf2-/- mice fed the indicated diet after 3 weeks. Data are presented as the mean ± 
SEM (n = 7–11/group). D: Plasma concentration of sulforaphane of Nrf2-/- mice fed the 
indicated diet for 6 weeks. Data are presented as the mean ± SEM (n = 5–6/group).  
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 Supplementary Figure 2—A: H&E staining of brown adipose tissue of mice fed the 
indicated diet for 14 weeks (original magnification, ×200; scale bars, 100 µm). B: 
Relative mRNA expression of genes implicated in uncoupling proteins (Ucp-1, Ucp-2, 
and Ucp-3), PGC-1α (Ppargc1a), and Deiodinase 2 (Dio2) in the brown adipose tissue 
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of mice fed the indicated diet for 14 weeks (n = 8/group). C: Relative mRNA expression 
of genes implicated in uncoupling proteins in quadriceps muscle of mice fed the 
indicated diet for 14 weeks. Results represent the mean ± SEM (n = 8/group). *P < 0.05, 
**P < 0.01 vs. NC. N.D., not detected. 
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 Supplementary Figure 3—Stromal vascular fraction cells were grown to confluence, 
then differentiation was induced as described in Methods. A: Quantitative real-time PCR 
determination of mRNA levels of Nrf2 target antioxidant genes in the absence or 
presence of sulforaphane (SFN; 0.2, 1, 2, or 5 µM) for 48 h in primary beige adipocytes 
isolated from inguinal WAT of wild-type mice (normalized against 36B4). B: The same 
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experiment as in (A) was repeated with primary beige adipocytes isolated from inguinal 
WAT of Nrf2-/- mice. Bar graphs represent mean ± SEM (n = 6/group). *P < 0.05, **P < 
0.01 vs. DMSO-treated adipocytes from wild-type mice. The difference was determined 
using a one-way ANOVA. Post hoc analysis was performed using Dunnett’s test. Cat: 
catalase, Sod1: superoxide dismutase 1, Hmox1: heme oxygenase 1, Prdx1: 
peroxiredoxin 1. C (left panel): At various stages of differentiation, cells were fixed and 
stained with oil red O. C (right panel): Quantitative real-time PCR determination of 
mRNA levels of adipocyte differentiation marker, fatty acid binding protein 4 (Fabp4), 
in wild-type and Nrf2-deficient beige adipocytes after 7 days of culture with 
maintenance medium. Bar graphs represent mean ± SEM (n = 6/group). **P < 0.01 vs. 
wild-type adipocytes. 
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Supplementary Figure 4—Immunoblot analysis of p-JNK (Thr183/Tyr185), JNK, 
p-ERK (Thr202/Tyr204), ERK, p-NF-κB p65 (Ser536), and NF-κB p65 using liver 
lysates of Nrf2-/- mice fed the indicated diet for 14 weeks. Each lane represents a liver 
lysate from a different animal (n = 8/group). Bar graphs represent normalized data of 
p-JNK/JNK, p-Erk/Erk, and p-NF-κB p65/ NF-κB p65 from two independent 
experiments, presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. NC. A.U.: arbitrary 
unit. 
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 Supplementary Figure 5— Relative mRNA expression of genes implicated in (A) Tnf-α, 
p22phox, and gp91phox, and (B) cell surface markers for macrophage, including Cd11b, 
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F4/80, and Cd68 in the epididymal white adipose tissue (eWAT) of mice fed the 
indicated diet for 14 weeks. C: FACS analysis of macrophage in eWAT of mice fed 
HFD or HFD-GR diet. Macrophages are defined as propidium 
iodide-CD45+NK1.1-CD3-CD19-TER119-CD11b+F4/80+ cells. Bar graphs show the 
number of macrophages in eWAT. D: M1-like and M2-like macrophages are defined as 
CD11c+CD206- and CD11c-CD206+ cells, respectively. Bar graphs show the 
percentage of M1- and M2-like macrophages, and the M1/M2 ratio. Data are presented 
as mean ± SEM (n = 8/group). *P < 0.05, **P < 0.01 vs. NC; #P < 0.05, ##P < 0.01 vs. 
HFD. 
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 Supplementary Figure 6—Immunoblot analysis of p-AMPKα (Thr172), AMPKα, 
p-ACC (Ser79), and ACC using lysates of liver, quadriceps muscles, intrascapular 
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brown adipose tissue (BAT), inguinal white adipose tissue (ingWAT), and epididymal 
WAT (eWAT) from mice on the indicated diet for 14 weeks. Bar graphs represent 
normalized data of p-AMPK/AMPKα and p-ACC/ACC from two independent 
experiments, presented as mean ± SEM (n = 8/group). **P < 0.01 vs. NC. A.U., 
Arbitrary unit. 
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